Literature DB >> 3917460

Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man.

M L Vance, D L Kaiser, W S Evans, M O Thorner, R Furlanetto, J Rivier, W Vale, G Perisutti, L A Frohman.   

Abstract

Human GH-releasing hormone [hGHRH-40 (GHRH)] stimulates GH release in a dose-dependent fashion when administered as single iv bolus doses or as continuous 90-min infusions. However, there has been variability in the GH responses, and it appears that there are waxing and waning effects of GHRH. To address whether these are a result of the dose of GHRH, time, or intermittent changes in sensitivity of the somatotrophs, we administered 6-h infusions of vehicle and different doses of GHRH to six normal men. In addition, an iv bolus injection of GHRH was given after 5.5 h of infusion to evaluate residual GH secretory capacity. The subjects were given infusions of either vehicle or GHRH (1, 3.3, and 10 ng/kg X min), followed by an iv bolus injection of 3.3 micrograms/kg on four separate occasions. GHRH infusions stimulated GH secretion compared to basal secretion. The changes from basal GH secretion (mean +/- SEM) were 2.0 +/- 1.6, 4.6 +/- 1.5, 12.7 +/- 5.1, and 8.2 +/- 1.8 ng/ml X h during the vehicle and GHRH (1, 3.3, and 10 ng/kg X min) infusions, respectively. The changes from basal GH secretion for 2 h after the iv bolus dose (after 5.5 h of infusion) were 33.3 +/- 8.7, 22.4 +/- 3.8, 14.0 +/- 3.6, and 10.5 +/- 2.0 ng/ml X h on the vehicle and GHRH (1, 3.3, and 10 ng/kg X min) infusion days, respectively. The magnitude of the GH response was inversely related to the GHRH infusion dose. The total amount of GH released during the 7.5-h study periods was not different among the vehicle and 3 GHRH infusion days. Thus, it appears that a finite amount of GH is released by GHRH. There was variability in the degree of responsiveness to the continuous infusions of GHRH. Surges of GH release occurred during the GHRH infusions, which may be attributed to intermittent secretion of a GH inhibitor, such a somatostatin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917460     DOI: 10.1210/jcem-60-2-370

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Long term growth hormone (GH)-releasing hormone and biosynthetic GH therapy in GH-deficient children: comparison of therapeutic effectiveness.

Authors:  M Bozzola; I Biscaldi; M Cisternino; F Severi; A Balsamo; E Cacciari; C Pellini; G Chiumello; G L Spadoni; B Boscherini
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

Review 2.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

3.  Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man.

Authors:  J A Goldman; M E Molitch; M O Thorner; W Vale; J Rivier; S Reichlin
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

4.  GH responsiveness to repeated GHRH or hexarelin administration in normal adults.

Authors:  A Sartorio; A Conti; S Ferrero; A Spada; G Faglia
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

Review 5.  Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.

Authors:  Monica Gola; Mauro Doga; Stefania Bonadonna; Gherardo Mazziotti; Pier Paolo Vescovi; Andrea Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

6.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

7.  Galanin infusion partially restores the blunted growth hormone responses to repeated growth hormone releasing hormone stimuli in normal adults.

Authors:  A Sartorio; A Spada; A Conti; G Grugni; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

8.  Different GH responsiveness to repeated GHRH administration in normal children and adults.

Authors:  A Sartorio; A Spada; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

Review 9.  Psychoneuroendocrine research in depression. II. Hormonal responses to releasing hormones as a probe for hypothalamic-pituitary-endorgan dysfunction.

Authors:  K P Lesch; R Rupprecht
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

10.  Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone.

Authors:  E del Pozo; K Schlüter; E Nüesch; J Rosenthaler; L Kerp
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.